Clinical Trials
20 trialsNCT07090499 2026-04-07
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
Phase 1 Recruiting
NCT04485013 2026-02-18
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Phase 1 Recruiting
NCT05325866 2026-02-04
FORTITUDE-301
Amgen
Phase 1/2 Completed
NCT07341737 2026-01-15
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
Phase 1/2 Not yet recruiting
NCT05194735 2025-11-10
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Alaunos Therapeutics
Phase 1/2 Terminated
NCT03993873 2025-10-01
SHIELD-1
Turning Point Therapeutics, Inc.
Phase 1 Active not recruiting
NCT04557449 2025-10-01
CDK4i
Pfizer
Phase 2 Active not recruiting
NCT07161713 2025-09-23
RESET
Stony Brook University
Phase NA Recruiting
NCT04802876 2025-03-21
ACROPOLI
SOLTI Breast Cancer Research Group
Phase 2 Active not recruiting
NCT05012397 2024-10-17
Milademetan in Advanced/Metastatic Solid Tumors
Rain Oncology Inc
Phase 2 Terminated
NCT06619886 2024-10-01
TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1 Not yet recruiting
NCT04682431 2024-03-22
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Ikena Oncology
Phase 1 Terminated
NCT04691375 2024-03-22
A Study of PY314 in Subjects With Advanced Solid Tumors
Ikena Oncology
Phase 1 Terminated
NCT04870034 2023-12-22
Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer
Roswell Park Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT05733000 2023-03-10
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Northwestern University
Phase 2 Recruiting
NCT02900664 2022-03-29
A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)
Novartis
Phase 1 Completed
NCT00101972 2022-02-22
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
MacroGenics
Phase 1 Completed
NCT01362790 2019-06-06
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01726296 2017-04-06
Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
Fox Chase Cancer Center
Phase NA Completed
NCT00004178 2011-06-10
Gene Therapy in Treating Patients With Cancer
Roger Williams Medical Center
Phase 1 Completed